top of page
コンファレンスクラウド
Page top

Direct Flight
UK Course

Welcome to the Direct Flight UK Course in London! Join us for an afternoon of networking and insightful discussions at the prestigious 116 Pall Mall - Institute of Directors.

Japanese life science startups will visit London to explore business partnering opportunities as they consider entering the UK market. Their goals include company formation, clinical trials, business partnerships, and securing investments. Please join us for a business lunch meeting!!

* This event is invitation only.

05 Dec

LONDON

Speaker

The Delegates

01

FEATURED INDUSTRY EXPERTS

01

Hedgehog MedTech

Medical Devices

Hedgehog logo.png

Founded in Tokyo in 2021, Hedgehog MedTech aims to bridge daily life and healthcare, focusing on digital solutions for headaches. The company is developing AI-driven diagnostic tools and a migraine treatment app using cognitive behavioral therapy (CBT) to support patients and improve treatment consistency. Their SaMD (Software as a Medical Device) offers headache diagnosis support and a symptom management tool, with plans for clinical trials in Japan in 2025. With partnerships in academia and healthcare, Hedgehog MedTech seeks to offer accessible, evidence-based migraine care, led by CEO Yumi Kawata, an experienced medical doctor with a background in public health and business.

FerroptoCure

Name

02

FerroptoCure Inc. is developing new cancer drugs that work in a unique way. Our approach targets ferroptosis, a type of cell death caused by oxidative stress. Cancer cells always resist ferroptosis to survive and grow. Our drugs aim to overcome this resistance.
Key points about our work:
-  We're targeting a mechanism that helps cancer cells survive and resist treatment
- Our drugs could potentially treat many types of cancer
-   We've already begun Phase I clinical trials
- We aim to bring a major innovation to cancer treatment
We are now fundraising (Series A) and looking for the opportunity for collaboration and out-licensing.

Pharmaceutical

FerroptoCure logo.png

CaTe Inc

03

Medical Devices

Cate logo.png

Name

Cardiac rehabilitation, centered on exercise therapy, is proven to benefit cardiovascular patients, yet Japan’s outpatient rehab participation remains low at 4–8%, hindered by limited access and the challenge of frequent hospital visits. While current remote rehab systems offer daily management and guidance, they lack effective digitization of exercise therapy near the Anaerobic Threshold (AT) needed for safety and efficacy. Our company's technology optimizes exercise load via smartphones or tablets, allowing AT-level standing exercises tailored to individual oxygen needs—no specialized equipment required. This convenient, at-home solution enables global access to essential cardiac rehabilitation.

Cooqoo (pre-startup)

Name

04

At Cooqoo, we are pioneering non-invasive tongue cancer treatment with SpaceORAL, a radiation therapy device that enhances patient outcomes and quality of life. Traditional surgery for tongue cancer, costing around $40,000, often results in speech impairment. SpaceORAL, a custom 3D-printed spacer, stabilizes the tongue with negative air pressure, allowing precise external radiation in just five outpatient visits, cutting treatment costs by half to $19,000. With strong clinical support from Tokyo Medical and Dental University Hospital and proven safety in initial trials, we aim to raise $3 million to advance trials, secure FDA approval, and make SpaceORAL the global standard in tongue cancer care.

Medical Devices

FELIQS

05

Pharmaceutical

Feliqs logo.png

FELIQS is a clinical-stage biopharma company addressing neurodegenerative retinal diseases with a de-risked approach, leveraging a proprietary platform, clinical evidence, and expert collaboration.

Our lead programs include:

  • FLQ-101 for retinopathy of prematurity (ROP), a small-molecule metabolic modulator and lipid peroxidation inhibitor, advancing to Phase 1b/2a in the US in 2024. With orphan drug designation and an expedited trial design, we aim for NDA submission by 2027.

  • FLQ-104 for Intermediate Dry AMD, a novel ferroptosis inhibitor targeting early intervention, with a Phase 1 trial planned for 2025.

Following a $2.5M seed round, we seek $25M in Series A funding to advance FLQ-101 in the US and Japan and secure key clinical trial partnerships.

Agenda

Agenda

05 December 2024

11:30

Registration & Welcome

12:00

Luncheon session & group photo

13:45

Delegation pitch

15:00

Business Matching Sessions

16:00

Reception & Networking

116-history-main.jpg

The Venue

Institute of Directors (IoD), London

Conveniently located in the heart of London, our venue provides the perfect setting for meaningful business discussions and networking opportunities.

Venue

Sponsor 

SUPPORTING OUR INITIATIVE

Ministry of Health, Labor and Welfare, Japan

Organiser

MRI logo.png
Contact

Direct Flight
UK Course

STAY AHEAD OF THE INDUSTRY

What

Direct Flight
UK Course in London

When

05 December, 2024

Where

Institute of Directors,

116 Pall Mall, London

Contact Us

To learn more, don’t hesitate to get in touch

Together, we'll go furtner 

for a view yet to be seen.

early stage technology management

© 2025 Biospire Japan Ltd.

bottom of page